Genotyping Assay Market by Technology (PCR, Sequencing, Micr

The global genotyping market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
 
Secondary Research
Secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the genotyping market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
 
Primary Research
In the primary research process, industry experts from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Industry experts from the supply side include CEOs, vice presidents, marketing and sales directors, business development managers, technology and innovation directors of companies manufacturing apoptosis assay products, key opinion leaders, and suppliers and distributors, whereas, the industry experts from the demand side include pharmaceutical R&D directors, researchers, biotechnologists, and related key personnel.
 
The APAC region is expected to grow at the highest CAGR during the forecast period
The genotyping market in the APAC is expected to grow at the highest CAGR during the forecast period. This is due to the increasing incidence of chronic diseases, and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases and the spread of infectious and microbial diseases in APAC countries. Global pharmaceutical and biopharmaceutical companies are also increasingly outsourcing clinical research and trials to companies in this region, which has increased the demand for genotyping products for drug profile assessment, drug efficacy and safety assessment, dosing determination, and drug response evaluation.
 
The prominent players in the global genotyping market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).